⁹⁰Y-ibritumomab Tiuxetan in B-cell Non-Hodgkin Lymphomas: Real-world Data From the United Arab Emirates.

ABSTRACT:

Purpose

B-cell non-Hodgkin lymphomas (NHLs) are significant contributors to cancer-related mortality. In this single-arm, retrospective cohort study, we aimed to examine the outcomes of a radioimmunotherapeutic modality, ⁹⁰Y-labeled ibritumomab tiuxetan (⁹⁰YIT) in B-cell NHLs.

Methods and materials

We conducted this study based on data from the United Arab Emirates lymphoma registry. All patients with NHL subjected to ⁹⁰YIT were eligible for inclusion. The country of research lacked a national autologous stem cell transplantation (ASCT) center, but many ASCT-eligible patients received ⁹⁰YIT. We investigated overall survival (OS) and event-free survival (EFS), as well as safety outcomes.

Results

Between 2004 and 2008, 54 of 1

SUBMITTER: Szakacs Z 

PROVIDER: S-EPMC9486419 | biostudies-literature | 2022 Sep-Oct

REPOSITORIES: biostudies-literature